MA39717A - Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs - Google Patents

Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs

Info

Publication number
MA39717A
MA39717A MA039717A MA39717A MA39717A MA 39717 A MA39717 A MA 39717A MA 039717 A MA039717 A MA 039717A MA 39717 A MA39717 A MA 39717A MA 39717 A MA39717 A MA 39717A
Authority
MA
Morocco
Prior art keywords
lymphocytes
methods
regulatory
increasing
ratio
Prior art date
Application number
MA039717A
Other languages
English (en)
Inventor
Jay A Berzofsky
Zhisong Chen
Samir Khleif
Robert Petit
Anu Wallecha
Original Assignee
Advaxis Inc
National Institutes Of Health Nih U S Dept Of Health And Human Services Dhhs U S Government Nih Divi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc, National Institutes Of Health Nih U S Dept Of Health And Human Services Dhhs U S Government Nih Divi filed Critical Advaxis Inc
Publication of MA39717A publication Critical patent/MA39717A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des procédés pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs. L'invention concerne en outre à des méthodes de traitement, de protection contre, et d'induction d'une réponse immunitaire contre une tumeur, comprenant l'étape d'administration à un sujet d'une souche de
MA039717A 2014-03-05 2015-03-05 Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs MA39717A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461948453P 2014-03-05 2014-03-05

Publications (1)

Publication Number Publication Date
MA39717A true MA39717A (fr) 2017-01-11

Family

ID=54055997

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039717A MA39717A (fr) 2014-03-05 2015-03-05 Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs

Country Status (14)

Country Link
US (1) US20170080064A1 (fr)
EP (1) EP3113794A4 (fr)
JP (1) JP2017508797A (fr)
KR (1) KR20160132033A (fr)
CN (1) CN106413745A (fr)
AU (1) AU2015227163A1 (fr)
BR (1) BR112016020364A2 (fr)
CA (1) CA2941405A1 (fr)
IL (1) IL247458A0 (fr)
MA (1) MA39717A (fr)
MX (1) MX2016011537A (fr)
RU (1) RU2016138601A (fr)
SG (1) SG11201607213QA (fr)
WO (1) WO2015134722A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
US8771702B2 (en) * 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2012125551A1 (fr) 2011-03-11 2012-09-20 Advaxis Adjuvants à base de listeria
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (fr) 2014-02-18 2017-10-11 Advaxis, Inc. Immunothérapie multi-cibles dirigée contre un biomarqueur
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
SG11201702857PA (en) * 2014-10-14 2017-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
TW201725050A (zh) * 2015-10-09 2017-07-16 創祐生技股份有限公司 臺北市南港區園區街3號17樓 Wr-09 抗癌疫苗組合
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
EP3645039A4 (fr) * 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Utilisation d'anticorps anti-fam19a5 pour le traitement de la fibrose
CA3069523A1 (fr) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. Souches bacteriennes immunostimulatrices modifiees et utilisations
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
CN110408634B (zh) 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3820992A2 (fr) * 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Souches bactériennes immunostimulatrices modifiées et utilisations associées
EP3844276A2 (fr) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Souches bactériennes immunostimulatrices modifiées et utilisations associées
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
PT2942391T (pt) * 2004-08-13 2018-10-09 Univ Pennsylvania Métodos de produção de vacinas não resistentes aos antibióticos
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5539411B2 (ja) * 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy
SG10201700392UA (en) * 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
RU2016137834A (ru) * 2014-02-25 2018-03-29 Адваксис, Инк. КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ ОПУХОЛЕЙ, СВЕРХЭКСПРЕССИРУЮЩИХ HER2/neu

Also Published As

Publication number Publication date
CN106413745A (zh) 2017-02-15
WO2015134722A2 (fr) 2015-09-11
EP3113794A2 (fr) 2017-01-11
IL247458A0 (en) 2016-11-30
KR20160132033A (ko) 2016-11-16
CA2941405A1 (fr) 2015-09-11
SG11201607213QA (en) 2016-09-29
MX2016011537A (es) 2017-05-01
JP2017508797A (ja) 2017-03-30
WO2015134722A3 (fr) 2015-10-29
RU2016138601A (ru) 2018-04-05
BR112016020364A2 (pt) 2018-01-16
US20170080064A1 (en) 2017-03-23
AU2015227163A1 (en) 2016-10-20
EP3113794A4 (fr) 2017-09-06

Similar Documents

Publication Publication Date Title
MA39717A (fr) Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2017000857A (es) Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
PH12017500982A1 (en) Heterodimeric antibodies that bind cd3 and cd38
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MY193723A (en) Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
MY198983A (en) Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
PH12017500745A1 (en) Bromodomain inhibitors
NZ777133A (en) Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
NZ732211A (en) Combination immunotherapy approach for treatment of cancer
SG10201808746QA (en) Methods for enhancing the efficacy of a tumor-directed immune response
MX2024010429A (es) Receptores solubles de interferon y usos de los mismos.
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MX2021007899A (es) Composiciones con inhibidor selectivo de la trans-se?alizacion de il-6.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
AU2016282877A8 (en) Antibodies against human CSF-1R for use in inducing lymphocytosis in lymphomas or leukemias
PH12017501897A1 (en) 2-thiopyrimidinones